Skip to main content
  • 6114 Accesses

Abstract

Modelling in cost effectiveness provides a common framework by which to systematically assess costs and outcomes, to represent uncertainty and to compare alternative courses of action. Having introduced decision trees for cost effectiveness modelling, we now move on to Markov models. This chapter provides an introduction to Markov models for cost effectiveness analysis, guiding you through when Markov modelling should be used; the concept of health states (which for the backbone or structure of a Markov model) and transition probabilities, Markov trace and cycles, time horizon and discounting.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    Answer 0.0561

References

  • Canadian Agency for Drugs and Technologies in Health (2006) Guidelines for the economic evaluation of health technologies: Canada, 3rd edn. Canadian Agency for Drugs and Technologies in Health, Ottawa

    Google Scholar 

  • Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ (2011) Discounting and decision making in the economic evaluation of health-care technologies. Health Econ 20(1):2–15. doi:10.1002/hec.1612, Epub 2010 May 12

    Article  PubMed  Google Scholar 

  • Evans KW, Boan JA, Evans JL, Shuaib A (1997) Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine. Pharmacoeconomics 12(5):565–577

    Article  CAS  PubMed  Google Scholar 

  • Kielhorn A, von der Schulenburg JMG (2000) The health economics handbook. Adis International, Chester

    Google Scholar 

  • Naimark DMJ, Bott M, Krahn M (2008) The half-cycle correction explained: two alternative pedagogical approaches. Med Decis Making 28(5):706–712

    Article  PubMed  Google Scholar 

  • National Institute for Health and Care Excellence (2013) Guide to the methods of technology appraisal 2013. http://publications.nice.org.uk/pmg9

  • O’Mahony JF, Paulden M (2014) NICE’s selective application of differential discounting: ambiguous, inconsistent, and unjustified. Value Health 17:493–496, http://dx.doi.org/10.1016/j.jval.2013.02.014. Published online ahead of print May 17 2013

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Edlin, R., McCabe, C., Hulme, C., Hall, P., Wright, J. (2015). Introduction to Markov Cost Effectiveness Models. In: Cost Effectiveness Modelling for Health Technology Assessment. Adis, Cham. https://doi.org/10.1007/978-3-319-15744-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-15744-3_5

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-15743-6

  • Online ISBN: 978-3-319-15744-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics